1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 27 OCTOBER 2014

Cancer Drug News 27 OCTOBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 16 pages

Industry Trend Analysis - Celgene Invests In Future With USD1bn Sutro Deal
Industry Brief - Genmab Reaches USD10mn Milestone In Daratumumab Collaboration
Industry Brief - ARIAD Updates On Final Recommendation By CHMP For Iclusig
Industry Brief - CTI Acquires Global Rights To Tosedostat
Industry Brief - Stellar/Biovest Enter KLH Supply Deal For BiovaxID NHL Immunotherapy
Industry Brief - Celator's CPX-351 Phase III Study Achieves Enrolment Target In High-Risk AML
Industry Brief - Merck's Keytruda Gains FDA Breakthrough Therapy Designation For Advanced NSCLC
Industry Brief - CHMP Recommends Xtandi For Treating Chemotherapy-Naïve MCRPCA
Industry Trend Analysis - Lynparza Likely To Be First Approved PARP Inhibitor
Industry Trend Analysis - Taiho Aims For Swift Entry To US MCRC Market
Industry Brief - Immunomedics' Isactuzumab Govitecan Gains ODD In Europe For PC
Industry Brief - Alchemia's HA-Irinotecan Phase III MCRC Trial Misses Primary Endpoint
Industry Brief - BI Initiates Global Phase III Study Of Nintedanib In Advanced CRC
Industry Trend Analysis - Sutent’s US Patents Stymie Generic Challenge For Now
Industry Brief - Epizyme Granted US Patent Allowance Covering PRMT5 Inhibitors
Industry Trend Analysis - Biotech Collaboration Indicates Arrival Of Novel Ab Technology
Industry Brief - ERYTECH Granted Patent In US For Asparaginase Test
Industry Brief - Medivation Licenses Pidilizumab From CureTech For Potential Oncology Applications
Industry Brief - Takeda Exercises Option For Novel Fleximer ADC
Industry Brief - Viamet Completes USD60mn Series D Financing; To Spin Out PCA Programme
Industry Brief - Innocrin Formed As PCA Spin-Out From Viamet
Industry Brief - Erytech Secures Cash For Advancing Oncology Therapeutic Developments
Industry Brief - Unum Therapeutics Launches With Funding

Table Of Contents

Cancer Drug News 27 OCTOBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.